The review found no eligible studies for this question.
Hysterectomy (simple or radical) with radiotherapy may leads to higher severe/serious adverse events compared with radiotherapy alone (low certainty).
It is very uncertain whether hysterectomy (simple or radical) with chemoradiotherapy changes overall survival Median compared with chemoradiotherapy alone (very low certainty).
It is very uncertain whether hysterectomy (simple or radical) with chemoradiotherapy changes progression or event‐free survival Median compared with chemoradiotherapy alone (very low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
Hysterectomy (simple or radical) with radiotherapy showed no clear difference in overall survival Median compared with radiotherapy alone (low certainty).
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus topoisomerase inhibitor compared with gemcitabine alone (high certainty).
Gemcitabine combinations leads to lower overall survival ‐ Gemcitabine plus taxane compared with gemcitabine alone (high certainty).
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus other agent(s) compared with gemcitabine alone (low certainty).
Fluoropyrimidine combinations showed no clear difference in overall survival compared with fluoropyrimidine alone (low certainty).
Gemcitabine combinations showed no clear difference in overall survival ‐ Gemcitabine plus platinum agent compared with gemcitabine alone (low certainty).
Gemcitabine combinations leads to lower overall survival ‐ Gemcitabine plus fluoropyrimidine compared with gemcitabine alone (high certainty).
Summary of findings table (subcomparison 4): targeted therapy agent… leads to lower overall survival compared with control intervention alone (high certainty).
Summary of findings table (subcomparison 4): targeted therapy agent… probably leads to lower progression‐free survival compared with control intervention alone (moderate certainty).
It is very uncertain whether summary of findings table (subcomparison 4): targeted therapy agent… changes toxicity compared with control intervention alone (very low certainty).
Cytarabine plus high‐dose methotrexate showed no clear difference in mortality (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).
Cytarabine plus high‐dose methotrexate probably leads to lower progression/relapse (median 3 years) compared with high‐dose methotrexate alone (moderate certainty).
Cytarabine plus high‐dose methotrexate showed no clear difference in treatment‐related mortality compared with high‐dose methotrexate alone (moderate certainty).